A GLOBAL, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, RESPONSE-ADAPTIVE DOSE-RANGING STUDY OF BMS-986177, AN ORAL FACTOR XIA INHIBITOR, FOR THE PREVENTION OF NEW ISCHEMIC STROKE OR NEW COVERT BRAIN INFARCTION IN PATIENTS RECEIVING ASPIRIN AND CLOPIDOGREL FOLLOWING ACUTE ISCHEMIC STROKE OR TRANSIENT ISCHEMIC ATTACK (TIA)
- Registry ID
- CV010031
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA
- Start date
- 2020-03-18
- Completion date
- 2022-03-29
- Last update
- 2018-11-29
Conditions
- ISCHEMIC ATTACK AND MINOR STROKE
- ACUTE ISCHEMIC STROKE
Related clinical trials
- OPTIMIZING REPERFUSION TO IMPROVE OUTCOMES AND NEUROLOGIC FUNCTION (ORION): A MULTICENTER,
DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED, PARALLEL-GROUP, PHASE 2/3 STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF JX10 IN ACUTE ISCHEMIC STROKE WITH LATE PRESENTATIONS
- PHASE 2/3 ADAPTIVE DESIGN, RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DM199 FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE (REMEDY2 TRIAL)
- A MULTICENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TWOPART, RANDOMIZED, PHASE 2 CLINICAL TRIAL TO ASSESS SAFETY, TOLERABILITY,
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OFBB-031 IN ACUTE ISCHEMIC
STROKE (AIS) PATIENTS
- NUANCE-ICAD: EFFECT OF GENOTYPE-GUIDED ORAL P2Y12 INHIBITOR SELECTION VS CONVENTIONAL CLOPIDOGREL THERAPY IN SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE: A PILOT PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT (PROBE) MULTI-CENTRE STUDY
- FOCAL CEREBRAL ARTERIOPATHY STEROID (FOCAS) TRIAL
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
View on source registry